Patents by Inventor Sriram Rampalli
Sriram Rampalli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11111250Abstract: The present invention relates to novel crystalline and amorphous polymorphic forms of Ribociclib(1) mono succinate. (I) Said crystalline forms may be useful in the improved preparation of oral dosage forms for the treatment of cancer.Type: GrantFiled: December 20, 2018Date of Patent: September 7, 2021Assignee: SHILPA MEICARE LIMITEDInventors: Sriram Rampalli, Lav Kumar Upalla, Suryanarayan Cherukuvada, Chanti Babu Patneedi, Gopala Krishna Dasari, Vijaya Murali Mohan Rao Seshagiri
-
Publication number: 20200339588Abstract: The present invention relates to novel crystalline and amorphous polymorphic forms of Ribociclib(1) mono succinate. (I) Said crystalline forms may be useful in the improved preparation of oral dosage forms for the treatment of cancer.Type: ApplicationFiled: December 12, 2018Publication date: October 29, 2020Applicant: SHILPA MEDICARE LIMITEDInventors: SRIRAM RAMPALLI, LAV KUMAR UPALLA, SURYANARAYAN CHERUKUVADA, CHANTI BABU PATNEEDI, GOPALA KRISHNA DASARI, VIJAYA MURALI MOHAN RAO SESHAGIRI
-
Patent number: 10435409Abstract: The present invention relates to a process for the preparation of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one or Ibrutinib of Formula (I). The present invention further relates to a process for the preparation highly pure 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one or Ibrutinib(I).Type: GrantFiled: February 2, 2017Date of Patent: October 8, 2019Assignee: SHILPA MEDICARE LIMITEDInventors: Sriram Rampalli, Lav Kumar Upalla, Chanti Babu Patneedi, Gopala Krishna Dasari, Akshay Kant Chaturvedi
-
Publication number: 20190040069Abstract: The present invention relates to a process for the preparation of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one or Ibrutinib of Formula (I).Type: ApplicationFiled: February 2, 2017Publication date: February 7, 2019Applicant: SHILPA MEDICARE LIMITEDInventors: SRIRAM RAMPALLI, LAV KUMAR UPALLA, CHANTI BABU PATNEEDI, GOPALA KRISHNA DASARI, AKSHAY KANT CHATURVEDI
-
Patent number: 9790185Abstract: The present invention relates to a process for the preparation of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide or Regorafenib (I). The present invention further relates to a process for the purification of 4-[4-({[4-chloro-3-(trifluoromethyl) phenyl] carbamoyl} amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide or Regorafenib (I) to provide highly pure material. The present invention further relates to a process for the preparation stable crystalline material of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methyl pyridine-2-carboxamide or Regorafenib (I) useful in the preparation of pharmaceutical compositions for the treatment of cancer.Type: GrantFiled: July 6, 2015Date of Patent: October 17, 2017Assignee: SHILPA MEDICARE LIMITEDInventors: Sriram Rampalli, Lav Kumar Upalla, Krishna Kumar Ramachandrula, Prashant Purohit, Chaturvedi Akshay Kant
-
Publication number: 20170204062Abstract: The present invention relates to a process for the preparation of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide or Regorafenib (I). The present invention further relates to a process for the purification of 4-[4-({[4-chloro-3-(trifluoromethyl) phenyl] carbamoyl} amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide or Regorafenib (I) to provide highly pure material. The present invention further relates to a process for the preparation stable crystalline material of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methyl pyridine-2-carboxamide or Regorafenib (I) useful in the preparation of pharmaceutical compositions for the treatment of cancer.Type: ApplicationFiled: July 6, 2015Publication date: July 20, 2017Applicant: SHILPA MEDICARE LIMITEDInventors: SRIRAM RAMPALLI, LAV KUMAR UPALLA, KRISHNA KUMAR RAMACHANDRULA, PRASHANT PUROHIT, CHATURVEDI AKSHAY KANT
-
Publication number: 20170107193Abstract: The present invention relates to process for the preparation of highly pure Lenalidomide (I). The invention also relates to crystalline Form-SL obtained by the process of the present invention., the said Form-SL being substantially pure and characterized by X-ray powder diffraction pattern comprising of at least seven peaks selected from 7.061, 12.860, 16.531, 18.698, 27.925, 33.212, 34.187, 35.253, 35.921 and 38.765±0.1°2?; a single un-split °2? peak at 7.813±-.1°2?; and a three-way split °2? peak at 20.467±0.1°2?. The invention further relates to pharmaceutical compositions comprising crystalline Form-SL of Lenalidomide, which may be useful for the treatment of cancer.Type: ApplicationFiled: August 1, 2014Publication date: April 20, 2017Applicant: SHILPA MEDICARE LIMITEDInventors: SRIRAM RAMPALLI, LAVKUMAR UPALLA, PRASHANT PUROHIT, AKSHAYKANT CHATURVEDI
-
Publication number: 20160340327Abstract: The present invention provides a process for preparing amorphous Cabazitaxel from the solvate form of Cabazitaxel. The present invention also provides novel diisopropyl ether solvate form of Cabazitaxel (I), and process for preparation thereof. Said amorphous Cabazitaxel and crystalline diisopropyl ether solvate of Cabazitaxel of the present invention can be utilized in preparing the pharmaceutical composition/s useful in the treatment of cancer.Type: ApplicationFiled: June 18, 2016Publication date: November 24, 2016Applicant: SHILPA MEDICARE LIMITEDInventors: SRIRAM RAMPALLI, PRASHANT PUROHIT, PRADEEP POTHANA, ANAND KUMAR DUNGA, AKSHAY KANT CHATURVEDI
-
Publication number: 20160264565Abstract: The present invention relates to a process for preparation of crystalline Form-SDI of Dasatinib (I). Said crystalline Form-SDI of Dasatinib is characterized by X-ray powder diffraction pattern comprising of at least seven 2?° peaks selected from the XRPD peak set of 5.8, 11.5, 12.7, 13.2, 17.3, 17.5, 18.1, 20.1, 20.5, 22.1, 25.4, 26.6, 26.8±0.20 2?°; IR spectrum having at least five absorption peaks selected from about 3390 cm?1, 2923 cm?1, 1621 cm?1, 1615 cm?1, 1537 cm?1, 1316 cm?1, 1061 cm?1, 815 cm?1 and 783 cm?1; and DSC isotherm comprising at least two endothermic peaks ranging between ?130° C. to 150° C., 160° C. to 175° C. or 280° C. to 290° C. The pharmaceutical compositions of the crystalline Form-SDI of Dasatinib or its hydrate thereof may be useful as an anti-cancer agent.Type: ApplicationFiled: April 24, 2014Publication date: September 15, 2016Applicant: SHILPA MEDICARE LIMITEDInventors: SRIRAM RAMPALLI, PRADEEP POTHANA, SURESH GARBAPU, PRASHANT PUROHIT, AKSHAYKANT CHATURVEDI
-
Publication number: 20160214961Abstract: The present invention relates to novel pharmaceutically acceptable substituted aryl acrylic acid addition salts of Crizotinib (I) or its hydrate or solvate thereof. The present invention further relates to processes for preparation of the said substituted aryl acrylic acid addition salts of Crizotinib (I). The present application also provides pharmaceutically acceptable substituted aryl acrylic acid addition salts of Crizotinib (I) or its hydrate or solvate useful as active pharmaceutical ingredient in pharmaceutical composition comprising thereof, possessing anti-cancer activity.Type: ApplicationFiled: September 3, 2014Publication date: July 28, 2016Applicant: SHILPA MEDICARE LIMITEDInventors: LAVKUMAR UPALLA, SRIRAM RAMPALLI, CHANTIBABU PATNEEDI, CHANDRASEKHAR DANGUDUBIYYAM, AKSHAYKANT CHATURVEDI
-
Publication number: 20150315164Abstract: The present invention provides a process for preparing amorphous Cabazitaxel from the solvate form of Cabazitaxel. The present invention also provides novel diisopropyl ether solvate form of Cabazitaxel (I), and process for preparation thereof. Said amorphous Cabazitaxel and crystalline diisopropyl ether solvate of Cabazitaxel of the present invention can be utilized in preparing the pharmaceutical composition/s useful in the treatment of cancer.Type: ApplicationFiled: December 18, 2013Publication date: November 5, 2015Applicant: SHILPA MEDICARE LIMITEDInventors: SRIRAM RAMPALLI, PRASHANT PUROHIT, PRADEEP POTHANA, ANAND KUMAR DUNGA, AKSHAY KANT CHATURVEDI
-
Patent number: 9145406Abstract: The present invention relates to an improved process for preparation of Dasatinib monohydrate Formula A, comprising the steps of: a) reacting the compound of Formula I with 1-(2-Hydroxyethyl)piperazine (Formula II) in the presence of acetonitrile solvent, an organic base and a phase transfer catalyst; b) heating the reaction mixture at 50-80° C.; c) adding water to the reaction mass obtained in step b); d) cooling the reaction mixture to a temperature below 35° C.; e) filtering and drying the material obtained in step d); f) optionally purifying the product obtained from step e); g) isolating the crystalline Dasatinib monohydrate.Type: GrantFiled: April 16, 2013Date of Patent: September 29, 2015Assignee: SHILPA MEDICARE LIMITEDInventors: Prashant Purohit, Sriram Rampalli, Mohanrao Seshagiri Vijaya Murali, Lavkumar Upalla, Pradeep Pothana
-
Publication number: 20150111929Abstract: The present invention provides an industrially suitable process for the preparation of substantially pure 4-{4-[({[4-chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide or Sorafenib and its tosylate salt, with a suitable impurity profile and without requirement of any additional purification steps. The present invention also provides Sorafenib base (II) as stable crystalline Form-SSB. The present invention further relates to a process for the preparation of crystalline Sorafenib tosylate Form-I which is free from contamination of any other polymorphic form of Sorafenib tosylate, for e.g. Form II or Form III, and does not involve any seeding requirement for crystallization step.Type: ApplicationFiled: December 31, 2012Publication date: April 23, 2015Inventors: Prashant Purohit, Sriram Rampalli, Mohanrao Seshagiri Vijaya Murali, Lavkumar Upalla
-
Publication number: 20150057446Abstract: The present invention provides an improved process for preparing N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazole carboxamide monohydrate or Dasatinib monohydrate (Formula A).Type: ApplicationFiled: April 16, 2013Publication date: February 26, 2015Inventors: Prashant Purohit, Sriram Rampalli, Mohanrao Seshagiri Vijaya Murali, Lavkumar Upalla, Pradeep Pothana